Loading
A phase 3 trial of Tarlatamab in small-cell lung cancer, run by Amgen, active and no longer recruiting.
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) is a phase 3 interventional study registered as NCT06117774 by Amgen, with 404 participants enrolled, started 2024-02-20 and due to reach its primary completion in 2030-04-20. Interventions recorded: Tarlatamab, Placebo. Conditions listed: Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Amgen, T-cell engagers (bispecific), Small-cell lung cancer.
Shares Tarlatamab, Limited-stage small-cell lung cancer, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Shares Tarlatamab, Amgen, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/